NGM Biopharmaceuticals (NYSE:NGM) Director Peter Svennilson purchased 84,939 shares of the firm’s stock in a transaction on Monday, October 21st. The stock was bought at an average cost of $11.75 per share, with a total value of $998,033.25.
Peter Svennilson also recently made the following trade(s):
- On Tuesday, July 30th, Peter Svennilson purchased 28,056 shares of NGM Biopharmaceuticals stock. The stock was bought at an average cost of $13.68 per share, with a total value of $383,806.08.
NYSE NGM opened at $12.87 on Friday. The company has a fifty day simple moving average of $13.71 and a two-hundred day simple moving average of $14.45. NGM Biopharmaceuticals has a 12-month low of $8.81 and a 12-month high of $19.27.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC acquired a new stake in shares of NGM Biopharmaceuticals during the third quarter valued at about $621,000. Nisa Investment Advisors LLC acquired a new stake in shares of NGM Biopharmaceuticals during the third quarter valued at about $81,000. Royal Bank of Canada acquired a new stake in shares of NGM Biopharmaceuticals during the second quarter valued at about $17,691,000. Svennilson Peter acquired a new stake in shares of NGM Biopharmaceuticals during the second quarter valued at about $229,762,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of NGM Biopharmaceuticals during the second quarter valued at about $1,870,000.
A number of research analysts have issued reports on NGM shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $26.00 price target on shares of NGM Biopharmaceuticals in a report on Wednesday, August 14th. B. Riley started coverage on shares of NGM Biopharmaceuticals in a report on Thursday, October 17th. They issued a “buy” rating and a $24.00 price target for the company. Finally, Zacks Investment Research raised shares of NGM Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Tuesday, August 27th. Six research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $24.17.
NGM Biopharmaceuticals Company Profile
NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.
Featured Story: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.